skip to main content

COPD inhaler escalation — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardRespiratory TherapeuticsCOPD inhaler escalationGPhC CRA

A smoker with confirmed COPD remains breathless despite optimised non-drug care and a short-acting bronchodilator. There is no asthma history, atopy or steroid-responsive feature. Which regular inhaled treatment should be offered?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — A long-acting muscarinic antagonist plus long-acting beta2 agonist

NICE offers LAMA plus LABA for persistent symptoms or exacerbations when COPD is confirmed and asthmatic or steroid-responsive features are absent. LABA plus ICS is considered when those features are present. Device choice follows an assessment of technique and preference.

Reference: NICE NG115: COPD — recommendations: https://www.nice.org.uk/guidance/ng115/chapter/Recommendations